Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study.
Forty cirrhotic patients with non-advanced hepatic encephalopathy were randomly allocated into groups which were given orally either two capsules three times daily of a preparation of Enterococcus lactic acid bacteria strain SF68 or 30 ml lactulose four times daily. The patients were evaluated over a 10-day course of treatment and for 10 days post-treatment. The Enterococcus SF68 preparation proved to be as effective as lactulose in lowering blood ammonia, and in improving mental state and psychometric performance. Moreover, the effects of Enterococcus SF68, contrary to that of lactulose, persisted longer after treatment withdrawal. Some patients reported diarrhoea and abdominal pain with lactulose. Lactulose is a standard therapy in the treatment of patients with hepatic encephalopathy. In this study, however, the use of the Enterococcus SF68 preparation was shown to offer advantages over lactulose in these patients.
D000328:Adult; D000368:Aged; D000641:Ammonia / Q000097:blood; D002214:Capsules; D002986:Clinical Trials as Topic; D004044:Dietary Proteins / Q000008:administration & dosage; D004187:Disaccharides / Q000627:therapeutic use*; D005260:Female; D006501:Hepatic Encephalopathy / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D006801:Humans; D007779:Lactobacillus acidophilus; D007792:Lactulose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013997:Time Factors
D002214:Capsules; D004044:Dietary Proteins; D004187:Disaccharides; D007792:Lactulose; D000641:Ammonia